Human Schwann Cells (HSwC)

Overview

Human Schwann Cells (HSwC) is a cell model used for research applications where physiologically relevant identity and donor background support interpretation of experimental readouts. Human Glial cells derived from Nerve (Schwann) within the Nervous system.

Schwann cells are major type of glial cells in peripheral nervous system. Schwann cells differentiate from cells of the neural crest during embryonic development, and they are stimulated to proliferate by some constituent of the axonal surface. Schwann cells can be either myelinating or non-myelinating. Whilst myelinating Schwann cells wrap around the axons of motor and sensory neurons to form the myelin sheath, non-myelinating Schwann cells do not wrap around the axons but still provide support and cushioning to the unmyelinated axons [1] . Each myelinating Schwann cell wraps around the shaft of an individual peripheral axon, forming myelin sheaths along segments of the axon. When an axon is dying, the Schwann cells surrounding it aid in its digestion, leaving an empty channel formed by successive Schwann cells, through which a new axon may then grow from a severed end. The number of Schwann cells in peripheral nerves is tightly regulated [2] . Their proliferation in vitro can be stimulated by various growth factors including PDGF, FGF, neuregulin, and others [3] . Schwann cells provide a relatively simple, well-defined, and accessible mammalian model for the study of numerous developmental diseases. It is also of clinical importance to understand the biology of Schwann cells, not only in the context of neuropathies and nerve regeneration, but also because the cells or their precursors may be especially well suited for implants to facilitate repair in the CNS. iXCells Biotechnologies provides high quality Human Schwann Cells (HSwC), which are isolated from human spinal nerve and cryopreserved at P1. Each vial contains ≥0.5 million viable cells. HSwC are characterized for expression of vimentin, S100, GFAP and CD90. They are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast, and fungi and can further expand no more than 3 passages in Schwann Cell Growth Medium ( Cat# MD-0055 ) under the condition suggested by iXCells Biotechnologies. Further expansion may decrease the purity. Figure 1. Human Schwann Cells (HSwC). The cells were recovered, and seeded at 10,000 cells/cm 2 following iXCells’ protocol. Phase contrast images were taken at the indicated time post recovery.

Key elements and design rationale

• Cell identity: Glial cells (Primary Cells)
• Source context: Nerve; Schwann; Nervous
• Donor background: Age: Embryonic
• Biosafety level: BSL-2 (follow your institution’s biosafety program and local regulations)

Product-specific elements (such as tissue source, donor background, and cell classification) help frame how results should be interpreted across assays and experimental conditions.

Biological background

Cells originating from the Nervous system are commonly studied to understand tissue-specific physiology, signaling, and responses to perturbations in controlled in vitro settings.

Across primary and specialty cell models, experimental outcomes can be influenced by donor heterogeneity, passage history, confluence, and media composition. For interpretation, it is common to validate key markers or functional phenotypes in the user’s assay context and to document culture variables consistently.

Research relevance and current trends

• Increasing use of primary and specialty cells to improve translational relevance for target biology and phenotypic screening.
• Adoption of 3D culture formats and co-culture systems to better capture tissue microenvironments and cell–cell interactions.
• Integration of functional readouts with single-cell and multi-omics profiling to connect phenotype with molecular state.
• Growth of human-relevant neural models (including glial components) to study circuit- and inflammation-linked phenotypes.

Common research applications

• Profile identity markers by flow cytometry or immunostaining in cultured cells
• Quantify neurite outgrowth and synaptic marker profiles in neural cultures
• Quantify functional responses to defined stimuli relevant to the model system
• Compare baseline phenotype across donors/conditions using gene expression profiling
• Measure neuroinflammatory signaling in neuron–glia or microglia-enriched models

Interpretation typically focuses on how a perturbation (e.g., cytokine exposure, metabolic stress, genetic manipulation, or compound treatment) shifts marker profiles or functional readouts relative to an appropriate control matched for donor and culture variables.

Notes for experimental interpretation

• Donor-to-donor heterogeneity can influence baseline phenotype and treatment response; include biological replicates when feasible.
• Passage number, confluence, and media composition can shift gene expression and functional readouts; track and report these variables consistently.
• Contamination control (including routine mycoplasma monitoring) supports reproducibility in downstream assays.
• Use appropriate negative/positive controls for the readout (e.g., unstimulated controls, pathway agonists/antagonists) to contextualize observed changes.

SKU:BHC18500061

Customization & Add-ons: Can't find the cell line you need—or require a custom cell-based solution for your project? We can help you source the best match or support custom cell line services for diverse research needs, including cell line sourcing and selection (species, tissue, and disease model matching), stable cell line engineering (overexpression, knockdown, or knockout via CRISPR/Cas9, shRNA, or sgRNA), reporter gene integration (GFP, RFP, luciferase, and other fluorescent or bioluminescent constructs), genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles), inducible expression systems (Tet-On/Off and other regulatable constructs), drug resistance marker selection (puromycin, G418, hygromycin, and others), custom growth and media optimisation for specific assay requirements, scale-up production for high-throughput screening campaigns, and authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.